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Aims We aimed to assess the prevalence and management of clinical familial hypercholesterolaemia (FH) among patients
with acute coronary syndrome (ACS).
Methods
and results
We studied 4778 patients with ACS from a multi-centre cohort study in Switzerland. Based on personal and familial
history of premature cardiovascular disease and LDL-cholesterol levels, two validated algorithms for diagnosis of clin-
ical FH were used: the Dutch Lipid Clinic Network algorithm to assess possible (score 3–5 points) or probable/definite
FH (.5 points), and the Simon Broome Register algorithm to assess possible FH. At the time of hospitalization for ACS,
1.6% had probable/definite FH [95% confidence interval (CI) 1.3–2.0%, n ¼ 78] and 17.8% possible FH (95% CI 16.8–
18.9%, n ¼ 852), respectively, according to the Dutch Lipid Clinic algorithm. The Simon Broome algorithm identified
5.4% (95% CI 4.8–6.1%, n ¼ 259) patients with possible FH. Among 1451 young patients with premature ACS, the
Dutch Lipid Clinic algorithm identified 70 (4.8%, 95% CI 3.8–6.1%) patients with probable/definite FH, and 684
(47.1%, 95% CI 44.6–49.7%) patients had possible FH. Excluding patients with secondary causes of dyslipidaemia
such as alcohol consumption, acute renal failure, or hyperglycaemia did not change prevalence. One year after ACS,
among 69 survivors with probable/definite FH and available follow-up information, 64.7% were using high-dose statins,
69.0% had decreased LDL-cholesterol from at least 50, and 4.6% had LDL-cholesterol ≤1.8 mmol/L.
Conclusion A phenotypic diagnosis of possible FH is common in patients hospitalized with ACS, particularly among those with
premature ACS. Optimizing long-term lipid treatment of patients with FH after ACS is required.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Familial hypercholesterolaemia † acute coronary syndrome † premature atherosclerosis † quality of care †
cardiovascular prevention
Introduction
Heterozygous familial hypercholesterolaemia (FH) is an autosomal-
dominant genetic disorder with an estimated prevalence of 1/200–
1/500 in the general population.1,2 Early identification of patients
with FH is important, because appropriate treatment may reduce
the risk of premature atherosclerosis.3,4 Mainly two diagnosis
algorithms are used to diagnose FH in the general population. The
Dutch Lipid Clinic Network algorithm is a scoring system based on
clinical factors endorsed by many guidelines worldwide, such as the
European Society of Cardiology, the National Lipid Association in
the USA, the International FH Foundation, and the European
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Atherosclerosis Society.1,5 – 7 The Simon Broome Register criteria
from NICE guidelines in the UK requires both an elevated
LDL-cholesterol .4.9 mmol/L (or total cholesterol .7.5 mmol/L)
along with history of premature atherosclerosis.8,9
Underdiagnosis of FH in the general population has recently been
recognized as an important issue, and for many patients with FH
who are unaware of their disease, the first clinical manifestation is
an acute coronary syndrome (ACS).10 Identifying FH during hospi-
talization for ACS would allow specific counselling for diet and car-
diovascular risk factors, ensure high-dose statin prescription at
discharge as well as appropriate referral to lipid clinics for identifica-
tion of family members.11 – 13 In addition, new lipid-lowering drugs
inhibiting proprotein convertase subtilisin/kexin 9 (PCSK9) might
be particularly promising in addition to maximal statin dose among
patients with FH.14 However, the proportion of patients hospita-
lized with ACS who have FH remains uncertain, with prevalence
ranging from 12% to .50% in patients ,60 years old according
to two small previous studies.15,16 To fill these gaps, we aimed to as-
sess the prevalence of FH and its 1-year management in a large
multi-centre cohort of patients with ACS.
Methods
Study population
This study was performed within the framework of the SPUM-ACS
(Special Program University Medicine-Acute Coronary Syndromes) co-
hort study designed to evaluate the determinants and consequences of
ACS in the general population. Details regarding the methods of the
SPUM-ACS study were previously reported,17 – 19 and are provided in
Supplementary material online. Of the 5713 patients in the SPUM-ACS
study hospitalized between 2009 and 2014, we excluded 935 patients
with missing values for total cholesterol, HDL-cholesterol, and triglycer-
ides (Supplementary material online, Figure S1). Thus, the final sample
for this analysis was 4778.
Ethics statement
The study protocol was approved by the institutional review board of all
participating centres and all patients provided written, informed
consent.
Diagnosis of familial hypercholesterolaemia
We assessed the presence of FH based on age, personal and family
history of premature atherosclerosis, and LDL-cholesterol levels.
We used the validated Dutch Lipid Clinic Network algorithm
recommended by many guidelines to diagnose FH in the general
population in central European countries.1,5 – 7 Clinical signs of lipid
accumulation in the tissue, as well as family history of elevated
LDL-cholesterol were not available in our study sample and missing
information was counted as zero in the Dutch Lipid Clinic algorithm.
A possible diagnosis was considered when the Dutch Lipid Clinic
Network score was 3–5, and a probable/definite FH when the score
was 6 or higher.20 We also used the Simon Broome Register criteria
from NICE guidelines in the UK. The diagnosis of possible FH re-
quires both an elevated LDL-cholesterol .4.9 mmol/L (or total
cholesterol .7.5 mmol/L) along with family or personal history of
premature atherosclerosis.8,9 Because signs of lipid accumulation in
the tissue or genetic tests for monogenic anomalies were not avail-
able, a confirmed diagnosis of definite FH according to the Simon
Broome algorithm could not be evaluated. Details regarding
measurement of covariates and the proportion of patients eligible
for each criteria are provided in Supplementary material online,
Tables S1 and S2.
Statistical analysis
One-way ANOVA and x2 tests or the Kruskal–Wallis rank test were
used for comparisons of clinical characteristics between those with/
without FH, for each diagnosis algorithm. Estimates of prevalence
were also reported for patients with premature ACS, defined by the oc-
currence of ACS ,55 years of age for men and ,60 years of age for
women. Stratified analyses for the prevalence of FH were reported ac-
cording to the use of lipid-lowering drugs before hospitalization. Sensi-
tivity analyses were done after excluding those with .3 days between
symptoms onset and lipid measurements, to take into account changes
in lipid levels after ACS. Further sensitivity analyses excluding patients
with severe hyperglycaemia .9 mmol/L at admission, or those under
dialysis or with acute renal failure with an estimated glomerular filtration
rate ,60 mL/min, or those consuming .14 units of alcohol were con-
ducted to exclude secondary causes of hyperlipidaemia. All hypothesis
tests are two-sided and the significance level set at 5%. Statistical ana-
lyses were performed using STATA statistical softwarew (Version 13,
STATA Corp, College Station, TX, USA).
Results
Among 4778 patients hospitalized for ACS, 78 [1.6%, 95% confi-
dence interval (CI) 1.3–2.0%] had a probable/definite FH, and 852
(17.8%, 95% CI 16.8–18.9%) had possible FH using the Dutch Lipid
Clinic Network algorithm (Figure 1). The Simon Broome algorithm
identified 259 (5.4%, 95% CI 4.8–6.1%) patients with possible FH.
Combining both algorithms, a total of 977 patients were identified
with either Dutch or Simon Broome criteria, and 77 (1.6%, 95%
CI 1.3–2.0%) had both probable/definite Dutch and Simon Broome
criteria. Most patients with possible FH identified with the Simon
Broome algorithm were also identified with the Dutch Lipid Clinic
algorithm (Supplementary material online, Figure S2). Among 1451
young patients with premature ACS, the Dutch Lipid Clinic algo-
rithm identified 70 (4.8%, 95% CI 3.8–6.1%) with probable/definite
FH, and 684 (47.1%, 95% CI 44.5–49.7%) patients with possible FH
(Figure 1). The Simon Broome Register algorithm identified 203
(14.0%, 95% CI 12.2–15.9) patients with possible FH among
patients with premature ACS.
Stratified analysis in 3353 patients not using lipid-lowering
drugs before hospitalization yielded about similar prevalence of
1.3% (95% CI 1.0–1.8%) for probable/definite FH, and 19.4%
(95% CI 18.0–20.7%) for possible FH according to the Dutch Lipid
Clinic algorithm (Supplementary material online, Figure S3A). Among
1425 patients using lipid-lowering drugs before hospitalization,
the prevalence of probable/definite FH reached 2.4% (95% CI
1.7–3.3%) (Supplementary material online, Figure S3B). Sensitivity
analysis in 3493 patients with blood draw within 72 h after symp-
toms onset, or in 4165 patients without acute renal failure or dialy-
sis, or in 3677 patients without severe hyperglycaemia at admission,
or in 4186 patients without alcohol excessive use yielded similar
results for prevalence of FH (Supplementary material online,
Figure S4).
Baseline characteristics of the 4778 participants with respect to
FH diagnosis are presented in Table 1. Compared with patients
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without FH, patients with FH were younger, had higher proportion
of personal or family history of premature coronary heart disease
(CHD), were more frequently smokers, but were less frequently
suffering from hypertension, diabetes, or pre-existing cardiovascular
disease. Baseline characteristics with respect to the use of
lipid-lowering drugs before hospitalization are presented in Supple-
mentary material online, Table S3. Compared with patients not using
lipid-lowering drugs before hospitalization, those with lipid-lowering
drugs were older, had more frequently pre-existing cardiovascular
disease or diabetes, but were less frequently current smokers.
Quality of care during and 1-year after hospitalization for ACS in
977 patients with possible FH according to either Dutch or Simon
Broome algorithm is shown in Tables 2 and 3. Among 78 patients
with probable/definite FH according to the Dutch Lipid Clinic algo-
rithm, 61.8% had an ST-segment elevation myocardial infarction,
and 69.7% were prescribed high-dose statins at discharge (Table 2
and Figure 2). After 1 year, 879 patients with possible FH were alive
and had available follow-up visit information, including a subsample
of 508 patients with measured LDL-cholesterol levels. Among the
69 patients with probable/definite FH according to the Dutch
Lipid Clinic algorithm, 44 (64.7%) had high-dose statins (Table 3
and Figure 2). In the subsample of 43 patients with probable/
definite FH and 1-year LDL-cholesterol available, 29 (69.0%)
had decreased their LDL-cholesterol of at least 50% over the
year, and 2 (4.6%) had an LDL-cholesterol levels of 1.8 mmol/L
or below (Table 3).
Discussion
In this large cohort study of patients with ACS, the prevalence of
probable/definite FH reached 1.6 and 4.8% when considering only
younger adults with premature ACS. These estimates are three to
six times higher than those of the general population using similar
diagnosis algorithms.2 More than a fourth of patients with prob-
able/definite FH were not discharged or were not using high-dose
statins 1-year after their hospitalization, or could not reach 50%
reduction of their LDL-cholesterol as recommended after ACS.
The prevalence of FH has never been studied in large cohorts of
patients with ACS. Previous studies had very small sample size, in-
cluded patients 20 years ago, and used heterogeneous definition
for FH, considering either genetic mutation rates or clinical cri-
teria.15,16,21,22 Studying 292 patients younger than 60 years old
with myocardial infarction in 1995, Dorsch et al. found a prevalence
of FH of 12.3%, based on LDL-cholesterol levels only.16 Using gen-
etically confirmed criteria for FH, about similar prevalence of 16.4%
was reported in 412 men younger than 60 years who underwent
coronary angiography for chest pain in the French part of Canada
between 1993 and 1995.21 In another study examining 102 patients
with CHD before the age of 60 years between 1986 and 1987, 54%
showed familial lipoprotein disorders, defined as elevated
LDL-cholesterol in the index cases and family members.15 In 33 fam-
ilies with two or more siblings with premature CHD before 55 years
of age studied in Utah, USA in the 1980s, 75% had elevated lipids,
Figure 1 Prevalence of clinical familial hypercholesterolaemia among patients with acute coronary syndrome (n ¼ 4778). FH, familial
hypercholesterolaemia.
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and 3% had monogenic alteration found in FH.22 More recently, a 2%
rate of rare genetic alteration in LDL-cholesterol receptor was re-
ported in young patients with premature myocardial infarction.23
In our study of .4700 patients with ACS, we found a high preva-
lence of 1.6% for probable/definite FH. As expected, prevalence of
probable/definite FH was higher in patients using statins before hos-
pitalization (2.4%), than those not taking statins (1.3%). These esti-
mates are higher than the prevalence of probable/definite FH
thought to be 0.2% (1/500) in the general population.1 In a large
population-based study in Denmark of nearly 70 000 participants,
probable/definite FH based on Dutch Lipid Clinic Network criteria
was identified in 0.5% (1/200) of participants,2 and genetically con-
firmed heterozygous FH reached 0.3% (1/244) in a recent Dutch
Study.24
Identification of FH is important as the disorder is associated with
early onset of CHD,3,4 but systematic screening of healthy adults
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Table 1 Baseline characteristics of patients with acute coronary syndrome and familial hypercholesterolaemia, by
diagnosis algorithm (n5 4778)
Dutch Lipid Clinic Network Simon Broome Register
Probable/definite
FH (>5 points)
Possible FH
(3–5 points)
No FH P-value Possible FH No FH P-value
Number 78 852 3848 259 4519
Percentage (95% CI) 1.6 (1.3–2.0) 17.8 (16.8–18.9) 5.4 (4.8–6.1)
Demographics
Age (years) 49.5 (9.3) 52.4 (10.0) 64.8 (11.5) ,0.001 51.6 (9.8) 63.8 (12.2) ,0.001
Female 18 (23.1) 172 (20.2) 818 (21.3) 0.7 62 (23.9) 946 (20.9) 0.25
Caucasian 72 (92.3) 791 (92.8) 3632 (94.4) 0.003 239 (92.3) 4256 (94.2) 0.18
Higher educationa 22 (30.1) 236 (30.4) 906 (27.1) 0.16 68 (28.8) 1096 (27.7) 0.7
Premature CHDb 70 (89.7) 684 (80.3) 697 (18.1) ,0.001 203 (78.4) 1248 (27.6) ,0.001
Family historyc 62 (79.5) 471 (55.5) 680 (17.9) ,0.001 128 (49.4) 1085 (24.3) ,0.001
Smoking status
Never 19 (24.4) 212 (25.0) 1261 (33.2) ,0.001 68 (26.2) 1424 (31.9) ,0.001
Former 16 (20.5) 159 (18.8) 1223 (32.2) 55 (21.2) 1343 (30.1)
Current 43 (55.1) 476 (56.2) 1318 (34.7) 136 (52.5) 1701 (38.1)
Elevated alcohol consumptiond 10 (13.7) 96 (12.3) 486 (14.2) 0.37 25 (10.5) 567 (14.1) 0.13
Comorbidities
Hypertensione 29 (37.2) 329 (38.6) 2294 (59.7) ,0.001 105 (40.5) 2547 (56.4) ,0.001
Diabetes mellitusf 4 (5.1) 89 (10.4) 763 (19.8) ,0.001 30 (11.6) 826 (18.29) 0.006
Pre-existing CVDg 9 (11.5) 147 (17.2) 1084 (28.2) ,0.001 36 (13.9) 1204 (26.7) ,0.001
Objective measures
Total cholesterol (mmol/L) 7.4 (1.6) 5.7 (1.2) 4.7 (1.1) 0.04 7.1 (1.2) 4.8 (1.1) ,0.001
LDL-cholesterol (mmol/L)h 6.6 (1.6) 4.3 (1.1) 3.2 (0.9) ,0.001 5.8 (1.1) 3.3 (1.0) ,0.001
HDL-cholesterol (mmol/L) 1.1 (0.3) 1.1 (0.3) 1.2 (0.4) ,0.001 1.1 (0.3) 1.2 (0.4) 0.03
Triglycerides (mmol/L) 1.3 (0.5) 1.5 (1.2) 1.4 (1.1) ,0.001 1.7 (1.3) 1.4 (1.1) ,0.001
Body mass index (kg/m2) 28.1 (4.9) 27.3 (4.4) 27.0 (4.3) 0.01 27.5 (4.5) 27.1 (4.3) 0.08
eGFR (mL/min) 93.5 (20.3) 98.6 (24.9) 88.6 (27.0) ,0.001 93.9 (23.5) 88.5 (27.1) 0.002
Medication use at admission
Aspirin 27 (34.6) 174 (20.4) 1265 (32.9) ,0.001 65 (25.1) 1401 (31.0) 0.045
Lipid-lowering drugs 34 (43.6) 203 (23.8) 1188 (30.9) ,0.001 88 (34.0) 1337 (29.6) 0.13
Statins 31 (39.7) 199 (23.4) 1155 (30.0) ,0.001 84 (32.4) 1301 (28.8) 0.2
Anti-hypertensives 23 (29.5) 242 (28.4) 1939 (50.4) ,0.001 75 (29.0) 2129 (47.1) ,0.001
Data are given as number (percentage) or mean (SD). P-values are results of one-way ANOVA, x2 tests, or Kruskal–Wallis rank tests, as appropriate.
CI, confidence interval; CHD, coronary heart disease; CVD, cardiovascular disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein; eGFR, estimated glomerular
filtration rate; FH, familial hypercholesterolaemia.
aDefined as a high school or university graduation or higher.
bAge of onset for ACS before 55 years in males and before 60 in females.
cBased on major cardiovascular event in a brother or father younger than 55 years old, or a mother or sister younger than 60 years old.
dMore than 14 units per week.
eDefined as a systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or use of blood pressure lowering drugs.
fBased on patients self-report, use of anti-diabetic medication/insulin, or haemoglobin A1c of ≥6.5%.
gDefined as CHD, ischaemic cerebrovascular disease, or periphery artery disease.
hIncluding 65 missing values because of elevated triglycerides level of 4.5 mmol/L or above.
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Table 2 Treatment initiated during and after an acute coronary syndrome, by presence of possible familial
hypercholesterolaemia (n 5 977)
Dutch Lipid Clinic
probable/definite FH
(>5 points)
Dutch Lipid Clinic possible
FH (3–5 points)
Simon Broome
Register possible
FH
Simon Broome and Dutch
Lipid Clinic FH (>5 points)
Diagnosis (n ¼ 943)
STEMI 47 (61.8) 459 (55.9) 147 (59.0) 46 (61.3)
NSTEMI 26 (34.2) 325 (39.6) 95 (38.1) 26 (34.7)
Unstable angina 3 (3.9) 37 (4.5) 7 (2.8) 3 (4.0)
Revascularization procedures (n ¼ 941)
Stent implantation 64 (84.2) 724 (88.4) 222 (89.5) 63 (84.0)
Balloon dilatation only 2 (2.6) 31 (3.8) 8 (3.2) 2 (2.7)
CABG 0 (0.0) 13 (1.6) 1 (0.4) 0 (0.0)
Medical treatment 10 (13.2) 51 (6.2) 17 (6.8) 10 (13.3)
Medication at discharge (n ¼ 935)
Statins 73 (96.0) 807 (98.9) 244 (98.0) 72 (96.0)
High-dose statinsa 53 (69.7) 617 (75.6) 195 (78.3) 52 (69.6)
Other hypolipemiantsb 6 (7.9) 21 (2.6) 12 (4.8) 6 (8.0)
Aspirin 76 (100.0) 814 (99.6) 248 (99.6) 75 (100.0)
Anti-hypertensivesc 71 (93.4) 779 (95.3) 229 (92.0) 70 (93.3)
Cardiac rehabilitation
(n ¼ 950)
50 (64.9) 548 (66.0) 176 (69.3) 50 (65.8)
Data are given as number (percentage).
STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; CAGB, coronary artery bypass grafting; FH, familial
hypercholesterolaemia.
aAtorvastatin 40–80 mg or rosuvastatin 20–40 mg.
bFibrates, ezetimibe, niacin, and resins.
cAngiotensin converting enzyme inhibitors, or angiotensin II receptor blockers, or b-blockers, or calcium-channel blockers, or diuretics.
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Table 3 Quality of care among patients with possible familial hypercholesterolaemia 1 year after hospitalization
for acute coronary syndrome (n5 879)
Dutch Lipid Clinic
probable/definite FH
(>5 points)
Dutch Lipid
Clinic possible
FH (3–5 points)
Simon Broome
Register possible
FH
Simon Broome and
Dutch Lipid Clinic FH
(>5 points)
Medication at 1-year (n ¼ 858)
Statins 64 (94.1) 710 (94.2) 212 (94.6) 63 (94.0)
High-dose statinsa 44 (64.7) 454 (60.2) 151 (67.4) 43 (64.2)
Other hypolipemiantsb 13 (19.1) 63 (8.4) 33 (14.7) 13 (19.4)
Aspirin 68 (100.0) 744 (98.5) 222 (99.1) 67 (100.0)
LDL-cholesterol targets reached (n ¼ 508)
≤1.8 mmol/L 2 (4.6) 98 (22.4) 12 (9.3) 2 (4.6)
≤2.6 mmol/L 16 (37.2) 287 (65.7) 61 (47.3) 16 (37.2)
LDL-cholesterol 50% reduction from
baseline without treatment (n ¼ 473)
29 (69.0) 170 (41.8) 75 (61.0) 29 (69.0)
Data are given as number (percentage).
FH, familial hypercholesterolaemia.
aAtorvastatin 40–80 mg or rosuvastatin 20–40 mg.
bFibrates, ezetimibe, niacin, and resins.
D. Nanchen et al.2442
remains a challenge.25 We found that among patients with possible
FH that were not using statins but aspirin before hospitalization for
ACS, 86% of them used statins 1-year after discharge, confirming
that in most cases, undertreatment of FH is due to underdiagnosis
rather than statins intolerance. During hospitalization for ACS,
screening for FH can be performed at low cost, by assessing familial
history of premature CHD and LDL-cholesterol levels. At hospital
discharge and after 1-year, we reported that more than a fourth of
patients with probable/definite FH and ACS were not using optimal
statin doses, and that nearly all could not reach 1.8 mmol/L for
LDL-cholesterol 1-year after their ACS. As future perspectives,
new lipid-lowering drugs targeting PCSK9 have shown large reduc-
tion of LDL-cholesterol levels compared with placebo in FH
patients with maximal tolerated statin doses, and phase III placebo-
controlled clinical trials examining long-term clinical outcomes are
ongoing.14 If efficacy for cardiovascular prevention is confirmed,
many patients with both ACS and FH might benefit from PCSK9
inhibitors, providing they are identified during the hospitalization.
Our study has several limitations. First, we did not perform gen-
etic molecular analysis to identify monogenic mutations associated
with FH. The detection rate for monogenic disorder is 25%
among patients with a diagnosis of possible FH, and 75% in pa-
tients with probable/definite FH.26,27 Thus, our estimates should
not be compared with prevalence studies of genetically confirmed
FH. However, the aim of our study was to estimate the prevalence
of clinical FH, because in patients with ACS and a phenotype diagno-
sis of FH, high-dose statins will be indicated, as recommended by
guidelines.1,5,7 In the setting of ACS, genetic tests might be used
for screening family members.7 Second, we were not able to assess
all clinical criteria of diagnosis algorithms, such as Achilles xanthoma
or LDL-cholesterol in family members. This is a limitation of previ-
ous studies about FH prevalence2,15,16 and this would likely under-
estimate the true prevalence of FH. However, when measurement
of LDL-cholesterol is systematically performed, such as in patients
with ACS, the importance of clinical signs of lipid accumulation in
the tissue to help identify patients with FH might be limited. In
addition, when family history of premature CHD is known, the im-
portance missing information about LDL-cholesterol levels in family
members may be limited, as 85% of families with premature CHD
have lipid abnormalities at the 95% percentile.22 Third, clinical diag-
nosis algorithms for diagnosis of FH have never been validated in
patients with ACS. However, accuracy of self-reported information
Figure 2 Type of statins used at discharge and after 1-year according to presence of familial hypercholesterolaemia. FH, familial
hypercholesterolaemia.
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regarding family history was similar in patients with and without pre-
existing cardiovascular disease.28 Finally, cholesterol levels have
been shown to decrease 24 h after admission for ACS. However,
blood samples were measured from the first blood draw in the
emergency department or at coronary angiography, and our sensi-
tivity analysis performed only in patients with a short time interval
between symptom onset and blood draw yielded similar results.
Conclusions
The high prevalence of FH in patients presenting with ACS may ad-
vocate for better identification of the disorder during the hospital
stay, in order to organize specific referral to lipid clinics or primary
care physicians for diet counselling, long-term maintenance of high-
dose statins, and identification of family members. In addition, new
lipid-lowering drugs targeting PCSK9 might represent a promising
therapeutic option in addition to statins for many patients with
ACS and FH.
Supplementary material
Supplementary Material is available at European Heart Journal online.
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